MICHIGAN RADIATION ONCOLOGY QUALITY CONSORTIUM

BCBSM 2026 Incentive Program Criteria Document

Pay for Performance=P4P
Gold Card=GC
CQI Value-Based Reimbursement=CQI VBR

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
P4P	01/01/2026-12/31/2026	Clinical Audit, CDA Team Meeting Participation, and Submission of Clinical Data	**1. Clinical Audit – 2 points** **a. Increase the overall data accuracy rate, target is >=95% as determined by a clinical audit of breast, lung, bone mets, and prostate data.** i. Metric score – 1 point. ii. Audit cases are patients with an RT end date within the 2025 calendar year (1/1/2025 - 12/31/2025). Patients with an RT end date in 2026 can be utilized for facilities with an insufficient number of cases. **b. Sufficient audit preparation and follow-up** i. Metric score – 1 point. ii. Audit materials available for review at the time of audit. iii. An appropriate staff member (CDA) attends the audit. iv. Corrections identified during the clinical audit are completed within 2 weeks of receiving them. **Audit Exemption Criteria for High-Performing Facilities:** • **Eligibility**: Facilities that achieved a clinical audit score of 98% or higher in 2025. • **Exemption:** These facilities will be exempt from the clinical audit for the subsequent year, 2026. • **Score Carry-Over:** During the exempt year, the score achieved in the preceding year, 2025, will be carried over. This means that high-performing facilities will automatically get 2 points for the clinical audit metric. • Facilities that achieve a clinical audit score below 98% in 2025 will continue with their annual 2026 clinical audit without exemption. • **Facilities that were granted an audit exemption in 2025 will be audited in 2026.** **2. CDA Team Meeting Attendance – 1 point** **a.** Metric Score – 1 point

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			b. CDAs must attend at least 3 CDA team meetings in 2026. **c.** Credit awarded based on Zoom attendance list. **d.** Only one person is required to attend and receive credit for facilities with multiple CDAs. **e.** If fewer than 3 meetings are held in 2026, the requirement will change to reflect the actual number of meetings held. **3. Increase in Submission of Clinical Forms – 3 points** **a. Target: >= 90% of baseline, on-treatment, and end-of-treatment forms submitted by the data entry deadline.** i. Metric Score - 1 point. ii. Relevant Forms: Breast (B1, B3, B5, B6, B7, *B9), Lung (L1, L2, **EOT** L3, L4, L5, L6, L7, *L8), Bone Mets (M1, M3, M4, M6) and Prostate (P1 /P2, P3, P4, P7). *Only the end of treatment date is needed on the B9 and L8 forms for lung SBRT & Hypofractionation/breast ultra-hypofractionation cases. iii. Metric calculation: $\frac{\textit{Patients who are missing at least 1 form}}{\textit{All eligible Patients}}$ iv. Eligible patients are defined as having an RT start date of 1/1/2026-7/31/2026. v. Data entry deadline: Form data must be submitted by 11/15/2026. vi. Follow-up forms are excluded from this measure. vii. If an SE2 form is submitted, all the required forms listed on the SE2 must be entered to receive credit. **b. Target: >= 60% Completion rate of 36-Month prostate P6 follow-up form** i. Metric Score – 1 point. ii. Relevant Form: CDA -month follow-up form (P6) iii. Metric Calculation:

<table>
<tr><th>Incentive Program</th><th>Measurement Period</th><th>Measure Description</th><th>Additional narrative describing the measure</th></tr>
<tr><td></td><td></td><td></td><td>
Submission of the 36-month P6 form due during 1/1/2026-7/31/2026
All 36-month P6 Forms due during 1/1/2026 - 7/31/2026

iv. The RT end date will be used to identify patients who are eligible for 36-month follow-up during the 1/1/2026-7/31/2026 measurement period.
v. The 36-month P6 follow-up form is expected to be completed 30 to 40 months after the RT end date.

c. Target: >=75% Completion rate of annual lung follow-up form
i. Metric Score -1 point.
ii. Relevant Form: CDA 1 year follow-up form (L11)
iii. Metric Calculation:
Submission of the 1-year L11 form due during 1/1/2026-7/31/2026
All 1-year L11 Forms due during 1/1/2026 -7/31/2026

iv. The RT end date on the L8 form will be used to identify patients who are eligible for the first-year follow-up during the 1/1/2026-7/31/2026 measurement period.
v. The 1-year L11 follow-up form is expected to be completed 9 to 15 months after the RT end date.
vi. Patients who completed RT between 1/1/2025 and 7/31/2025 but are terminated earlier than 12 months after their RT end date (the 1st year follow-up), will not be excluded from this measure. In this case, L11 forms should be filled out at the same time an SE2 (early termination form) is completed.

P4P Scoring:
<table>
<tr><th colspan="2">Clinical Audit, CDA Team Meeting Participation, and Submission of Clinical Data Score Breakdown</th></tr>
<tr><td colspan="2"><u>6 Total Points:</u></td></tr>
<tr><td>1 point</td><td>Clinical Audit data accuracy</td></tr>
<tr><td>1 point</td><td>Sufficient audit preparation and follow-up</td></tr>
</table>
</td></tr>
</table>

<table>
<tr><th>Incentive Program</th><th>Measurement Period</th><th>Measure Description</th><th>Additional narrative describing the measure</th></tr>
<tr><td></td><td></td><td></td><td>
<table>
<tr><td>1 point</td><td>CDA Team meeting attendance</td></tr>
<tr><td>1 point</td><td>Submission of baseline, on-treatment, and end-of-treatment clinical forms</td></tr>
<tr><td>1 point</td><td>Submission of P6 36-month form</td></tr>
<tr><td>1 point</td><td>Submission of L11 1 year form</td></tr>
<tr><td colspan="2">• All metrics met: 6 points.
• Some metrics met: Partial points given based on the breakdown above.</td></tr>
</table>
</td></tr>
<tr><td>P4P</td><td>01/01/2026-09/30/2026</td><td>Timely Submission of High-Quality Physics & Dosimetry Data</td><td>
A. Physics & dosimetry information is submitted within 6 weeks of end of treatment for >=85% of breast, lung, bone mets, and prostate patients from the 2026 performance year.
a. “Physics & dosimetry information” refers to the patient- specific Radiotherapy Technical Details form and full DICOM data set where required. * Credit is received if the patient’s information is submitted within 6 weeks of the patient’s RT end date.
*Note that DICOM data upload is not required for bone mets patients treated with a 2D or 3D technique.

Population: Patients with RT start date of 01/01/2026-09/30/2026 and whose physics data are due by the November 2026 data entry deadline.

B. Physics & dosimetry information is error-free according to database-specific Physics-Data Checker reports for >=95% of 2026 patients.
a. Any errors on the Physics-Data Checker reports for 2026 patients must be resolved by the November 2026 deadline for a case to be counted as “error-free.”
Population: Patients with RT start date of 01/01/2026-09/30/2026.

C. Physics data audit score achieved is >=97% and the facility demonstrates sufficient audit preparation and follow-up.
a. Overall data accuracy is >=97% as determined by an audit of breast, lung, bone mets, and prostate cases. Audit cases are patients with an RT end date within the 2025 calendar year (1/1/2025-12/31/2025).
</td></tr>
</table>

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			b. Sufficient audit preparation and follow-up, which includes: i. Audit materials available for review at the time of audit. ii. Appropriate staff member (physicist or dosimetrist) attends the audit. iii. Corrections identified during the audit are completed within 2 weeks of receiving them. **Audit Exemption for High-Performing Facilities:** • Facilities that achieved a physics audit score of 99% or higher in 2025 will be exempt from the physics data audit in 2026. • During the exempt year, the score achieved in the previous year will be carried over. This means that high-performing facilities will automatically meet physics data audit Metric C. • Facilities with a physics audit score below 99% in 2025 will continue with their annual 2026 physics audit without exemption. • **Facilities that were granted an audit exemption in 2025 will be audited in 2026.** **P4P Scoring:** • Three Metrics Met 6 points • Two Metrics Met 4 points • One Metric Met 2 points • No Metrics Met 0 points
P4P **CQI VBR**	**01/01/2026-09/30/2026**	**Increase the collaborative-wide utilization of prone positioning for breast cancer radiation treatment.**	**Population:** Breast cancer patients enrolled in MROQC during Q1-Q3 2026. **Numerator:** Breast cancer patients who receive whole or partial breast radiation only in the prone position. **Denominator:** Breast cancer patients who do not have any of the following exclusions for prone positioning during the measurement period: -Lack prone treatment equipment -Cannot tolerate prone positioning -Refuses prone positioning after being informed of its potential benefits -Is receiving regional (nodal) irradiation -Have small breasts, defined as a cup size A or a breast PTV_eval volume ≤ 1000cc. **

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			Small breasted patients will be excluded from the denominator for purposes of this measure. These patients may, however, be treated in the prone position if the patient and the oncologist choose to do so but if they are excluded, it will not affect the facility's calculation of the measure. • Data from the BRTD will be used for this measure as well as the B7, which will capture any contraindications for treatment with prone by the physician. • The MROQC collaborative will use breast data from node negative patients with an RT start date of 01/01/2026-9/30/2026 for this measure. The score reported will be the **collaborative performance at the end of Q3 2026. This will allow for measurement/improvement, and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.
P4P **GC** **CQI VBR**	**01/01/2026-09/30/2026**	**Increase the baseline and post-radiation treatment (RT) completion rate of standard of care arm measurements for lymphedema assessment in node positive breast cancer patients treated to regional fields.** **A. >=50% of breast patients treated to regional fields with a baseline measurement (B7 or B9) in 2025 must have a follow-up measurement (B10 or B14) completed and reported in cm within Q1-Q3 of 2026. *** **B. >=50% of breast patients treated to**	**Population:** Node positive breast cancer patients with RT start dates of 01/01/26-09/30/26. **Numerator:** Number of node positive breast cancer patients who receive the standard of care arm measurements for lymphedema assessment at baseline (pre-RT) and in follow-up (post-RT). **Denominator:** Total number of node positive breast cancer patients who were treated with regional fields *(excluding IMN only)* • The following patients will be excluded from the measure: ○ Patients who decline the measurements. ○ Patients who have a virtual visit. ○ Patients who did not complete RT • Documentation of this measure will come from the B7 or B9 forms (Baseline) and/or B10 or B14 (Follow-Up) as well as the BRTD (to determine if the patient is node positive). • MROQC will use facility data from node positive breast patients with baseline measurements in 2025 who will be due for a follow-up in Q1-Q3 2026 as well as cases with an RT start date of 01/01/2026-09/30/2026 to capture baseline

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
		regional fields with a RT start date within Q1-Q3 of 2026 must have a baseline measurement (B7 or B9) reported in cm and complete nodal irradiation data (dose to irradiated nodal groups is reported and nodal contours are named according to TG263 guidelines).	measurements for this measure. The score reported will be the facility performance rate as of the end of Q3 2026 (using Q1-Q3 2026 overall rate). This will allow for measurement/improvement, and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.
P4P **CQI VBR**	**01/01/2026-09/30/2026**	**For treatment of lung cancer with hypofractionation (6-20 fractions), MROQC Consensus Quality Guidelines are achieved for at least 75% of patients collaborative-wide.**	**Population**: Lung cases treated with hypofractionation with RT start dates of 01/01/26-09/30/26. **Numerator:** All lung cases treated with hypofractionation meeting the MROQC Consensus Quality Guidelines. **Denominator:** All lung cases treated with hypofractionation. • The lung radiotherapy technical details (LRTD) form will be used to determine fractionation and the lung DICOM will be used to identify if organs at risk (OARs) are contoured per the MROQC Consensus Quality Guidelines. • The MROQC collaborative will use lung data from patients treated with hypofractionation with an RT start date of 01/01/2026-9/30/2026 for this measure. The score reported will be the collaborative performance at the end of Q3 2026. This will allow for measurement/improvement, and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.
P4P **GC** **CQI VBR**	**01/01/2026-09/30/2026**	**Increase the utilization rate of bone mets treatments consisting of 5 fractions or fewer.**	**Population:** All bone mets cases who start treatment in Q1-Q3 2026 **Numerator:** Bone mets cases receiving 5 or fewer fractions **Denominator:** All bone mets cases except for those being treated for cord compression

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			• Data from the baseline clinical data form (M1), physician baseline (M4), and the bone mets physics survey (MRTD) for bone mets cases with a radiotherapy (RT) start date of 1/1/2026 through an RT start date of 9/30/2026 will be used to assess this measure. The physics survey (MRTD) will be used to determine the number of fractions delivered. • The score reported will be the facility's performance as of the end of Q3 2026 (using Q1-Q3 2026 overall rate). This will allow for measurement/improvement and allow for time to finalize data collection and determination of a facility's final rate.
P4P **GC** **CQI VBR**	**01/01/2026-09/30/2026**	**Increase the rate of physics consultation for bone metastases reirradiation. *** ****For cases where there is concern for toxicity due to cumulative dose (Type 1 or Type 2 reirradiation), the physics consult must occur prior to physician approval. For Type1 reirradiation cases with no concern for toxicity, the consult must occur prior to the start of treatment.***	**Population:** Patients undergoing reirradiation treatments within the participating radiation oncology departments. **Numerator**: The number of reirradiation cases with documented medical physics consultations. **Denominator**: The total number of reirradiation cases. • For bone mets reirradiation cases, the bone mets physics survey (MRTD) will be the source for documentation of a physics consult prior to final physician approval of a treatment plan. • For Type 1 reirradiation where there is overlap of irradiation volumes but no concern for toxicity from cumulative doses, physics must be consulted prior to treatment. • MROQC will use facility data for bone mets reirradiation cases with an RT start date of 01/01/2026-09/30/2026 for this measure. The score reported will be the facility performance as of the end of Q3 2026 (using Q1-Q3 2026 overall rate). This will allow for measurement/improvement, and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.
P4P **GC** **CQI VBR**	**01/01/2026-09/30/2026**	**Improve the percentage of patients with intact, localized, high-risk prostate cancer patients receiving definitive**	**Population:** Patients with Intact, High-risk prostate cancer per NCCN guidelines with RT start dates of 01/01/2026-09/30/2026. **Numerator:** Number of high-risk patients recommended to receive an intended ADT duration

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
		radiotherapy that are recommended to receive long-term androgen deprivation therapy (ADT).	in accordance with ASTRO/AUA guidelines (18-36 months). **Denominator:** Number of patients with intact, high-risk prostate cancer per NCCN guidelines. • The P3 will capture the intended duration, clinical trial participation, and patient refusal (*possible exclusions*). Risk grouping will come from either the MUSIC baseline data (matching facilities) or the P7 (facilities without a MUSIC partner). • MROQC will use facility prostate case data with an RT start date of 01/01/2026-09/30/2026 for this measure. The score reported will be the facility performance as of the end of Q3 2026 (using Q1-Q3 2026 overall rate). This will allow for measurement/improvement and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.
P4P **GC** **CQI VBR**	**01/01/2026-09/30/2026**	**Increase MRI utilization for intact prostate cancer patients receiving definitive radiotherapy.**	**Population:** Patients with intact prostate cancer with RT start dates of 01/01/2026-09/30/2026 undergoing treatment type external beam radiation therapy with or without brachytherapy. **Numerator:** All prostate patients with an MRI in the last 12 months report on the P3 form. **Denominator:** All intact patients, with treatment type = "EBRT alone" or "Combination therapy of EBRT and brachytherapy' • Patients unable to undergo MRI will be excluded. Examples: ○ Patient declined for reasons such as claustrophobia, personal preference, or cost ○ Implanted medical device ○ Lack of insurance coverage ○ Post-operative case • The prostate physics survey (PRTD) will be used to collect data on the number of intact prostate cancer patients receiving EBRT. The physician androgen deprivation form (P3 form) will be used to identify patients who underwent MRI in the last 12 months. • MROQC will use facility prostate case data with an RT start date of 01/01/2026-09/30/2026 for this measure. The score reported will be the

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			facility performance as of the end of Q3 2026 (using Q1-Q3 2026 overall rate). This will allow for measurement/improvement and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in early 2026.
P4P	**01/01/2026-12/31/2026**	**Collaborative-Wide Meeting Participation – Clinical Champion (per MROQC CC Attendance Policy)**	All Clinical Champions are expected to attend the three (3) Collaborative Meetings held each year. Full Pay for Performance (P4P) points are awarded for attendance at the 3 meetings. When the Clinical Champion cannot attend a substitute may be allowed to represent the facility. A substitute is allowed once a year; the Clinical Champion must attend at least two of the meetings and can send a substitute for the third and still receive full P4P points. If two substitutes attend in a calendar year, only partial points will be given. Ideally, the substitute is another Radiation Oncologist from that facility that treats MROQC patients. Other Radiation Oncologists are acceptable. • In certain cases (example: a small facility with only 1-2 Radiation Oncologists), another physician is acceptable such as the Chief Medical Officer (CMO), the Chief of Quality, or a physician involved in Radiation Oncology cases. • Residents, Physician Assistants (PA), Nurse Practitioners or non-physicians are not acceptable substitutes. 1. Friday, February 13th, 2026 (virtual) 2. Friday, May 15th, 2026 3. Friday, October 16th, 2026
P4P	**01/01/2026-12/31/2026**	**Collaborative-Wide Meeting Participation – Physics Lead (or designee)**	The facility's Physics Lead (or designee-i.e., another physicist or a dosimetrist who works on MROQC) is expected to attend all the MROQC Collaborative Meetings for 2026. 1. Friday, February 13th, 2026 (virtual) 2. Friday, May 15th, 2026 3. Friday, October 16th, 2026
P4P	**01/01/2026-12/31/2026**	**Collaborative-Wide Meeting Participation – Clinical Data Abstractor (or designee)**	MROQC CDAs (or designee-i.e., another CDA or someone who works on MROQC not covering another role at a meeting) are expected to attend all the MROQC Collaborative Meetings for 2026. 1. Friday, February 13th, 2026 (virtual) 2. Friday, May 15th, 2026 3. Friday, October 16th, 2026

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
P4P	**01/01/2026-12/31/2026**	**Bonus Measure: MROQC Physician Engagement**	MROQC Physician Engagement (10 Bonus Points) *Not to exceed 100 points total on the P4P scorecard.* • Lead author on an MROQC publication *(Counts as 2 items)* • Lead a skills workshop *(Counts as 2 items)* • Present at an MROQC collaborative-wide meeting *(non-leadership role only)* • Present on MROQC at a national meeting *(Cannot be a resident)* • Attend 5 working group meetings in 2026 *(Total across practice physicians; 1 physician counts per meeting i.e., no double points if 2 attend the same meeting)* • Coauthor on an MROQC publication • Attend 3 case review sessions • Propose a new quality measure: provide reasoning to implement the measure, work with the MROQC data team to review supporting data and present the measure to the relevant working group Metrics of Success: 5 or more items achieved 10 points 3-4 items achieved 5 points 1-2 items achieved 1 point Qualifications: 1. Must be a Clinical Champion or Participating Physician 2. Cannot be a resident
CQI VBR	**01/01/2026-09/30/2026**	**At least 80% of breast cancer patients who report using cannabis in the past 30 days are provided an MROQC cannabis education document during treatment.**	**Population:** Breast cancer patients treated at MROQC facilities who report cannabis use within the past 30 days in Q1-Q3 2026. **Numerator:** Breast cancer patients treated in MROQC during Q1-Q3 2026 who report using cannabis within the past 30 days who are offered with the MROQC cannabis education document. **Denominator:** Breast cancer patients treated in MROQC during Q1-Q3 2026 who report using cannabis within the past 30 days prior to treatment start.

Incentive Program	Measurement Period	Measure Description	Additional narrative describing the measure
			• "Provided" equals "offered" the education document. • Data will be collected from B1 (patient), B5 (CDA) MROQC will use breast data from patients with an RT start date of 01/01/2026-9/30/2026 who report cannabis use within the past 30 days for this measure. The score reported will be the collaborative performance at the end of Q3 2026. This will allow for measurement/improvement, and allow for time to finalize data collection, determination of final rate, and scoring before scores are due to BCBSM in late 2026.